Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10159306 | 0.94 | MAPK1 (0.51) | KDM5AEPHX2EPHX1HTTKDM5C | |
| SCHEMBL10159314 | 0.90 | KDM5A (0.49) | KDM5AEPHX2EPHX1KDM5CKDM5B | |
| SCHEMBL10156602 | 0.83 | HTT (0.46) | EPHX2EPHX1HTTMAPK1POLB | |
| SCHEMBL13853804 | 0.80 | HTT (0.56) | HTTKDM5BMAPK1POLB | |
| SCHEMBL13853823 | 0.80 | HTT (0.56) | HTTKDM5BMAPK1POLB | |
| SCHEMBL12522289 | 0.79 | EPHX2 (0.71) | EPHX2EPHX1 | |
| SCHEMBL13853789 | 0.79 | HTT (0.59) | HTTKDM5BMAPK1POLB | |
| SCHEMBL14853467 | 0.79 | KDM5A (0.46) | KDM5AEPHX2EPHX1KDM5CKDM5B | |
| SCHEMBL10155582 | 0.78 | EPHX2 (0.56) | EPHX2EPHX1 | |
| SCHEMBL965099 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | KDM5A 4286/4885EPHX2 2975/4885EPHX1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.